Scientists uncover new DNA role in modifying gene function

Apr 10, 2011

For years, scientists have thought of DNA as a passive blueprint capable only of producing specific proteins through RNA transcription. Now, research led by scientists from the Florida campus of The Scripps Research Institute has shown DNA can also act to fine-tune the activity of certain proteins known as nuclear receptors.

These new findings may make it possible to design therapies that could activate specific in a highly targeted manner in a number of important diseases including , , autoimmune disease, and cancer.

The study was published April 10, 2011, in the journal Nature Structural & Molecular Biology.

"This study offers the first direct evidence of what we now recognize as critically important interactions," said team leader Patrick R. Griffin, PhD, chair of the Department of Molecular Therapeutics and director of the Translational Research Institute at Scripps Florida. "This new understanding could lead to the development of ways to promote highly targeted activity, which is exactly what you need in order to produce safe and effective therapies."

The new study focuses on the interactions between a complex comprising the vitamin D receptor and the retinoic X receptor and their ligands, vitamin D and 9-cis-retinoic acid (a metabolite of vitamin A), respectively, as well as DNA, and a coregulatory protein. Receptors are proteins to which one or more specific kinds of signaling molecules bind.

Scientists at Eli Lilly and Company collaborated on this study to better understand how vitamin D works at its most basic level, given that vitamin D plays a major role in bone health and is thus linked to the company's research platform in osteoporosis.

"These findings will potentially enable us to design safer medicines that work via the vitamin D pathway to help the osteoporotic patient," said Jeffrey A. Dodge, PhD, senior research fellow at Lilly. "Specifically, the technology developed at Scripps to understand these receptor ligand interactions has been critical and is a great example of industry-academia collaboration to solve important scientific questions."

Dynamic Interactions

In the new study, the scientists used a technology known as hydrogen-deuterium exchange (HDX) mass spectrometry to measure the interaction of various ligands with the vitamin D receptor complex. Ligands can be small synthetic compounds, hormones, other proteins, or DNA and they bind to large molecules such as proteins and change these molecules' behavior. In this study, the ligands were vitamin D, a metabolite of vitamin A, DNA, and a coactivator protein known as SRC1 (steroid receptor coactivator 1).

"HDX mass spectrometry is a high-precision, high-sensitivity mapping technique," Griffin explained. "With it, we can find the specific regions of the protein complex that are altered upon interaction with ligand. This information can be used to infer structural changes that are the result of a specific interaction."

In their research, the scientists found that DNA can actually alter the structure and function of the receptor complex through a wide variety of long-range structural effects. These long-range effects had been hypothesized, but this study is the first to actually detect them directly with high spatial resolution. The changes wrought by these dynamic interactions were impressive.

The study shows these binding events have substantial consequences; for example, that the DNA binding at one site alters the stability of both the ligand binding site as well as coactivator interaction surface at opposite ends of the complex and vice versa. Those alterations influence a number of key processes, from coactivator-mediated interactions with various cofactors to the modification of the DNA binding domain so that the receptor can recognize specific DNA sequences.

"There is an elaborate biochemical dialogue going on between the receptor, ligand, coregulatory proteins, and the specific sequence that the nuclear receptor complex is bound to," said Griffin. "But until this study, it was not completely clear what the structural basis for this crosstalk was."

Explore further: Molecular gate that could keep cancer cells locked up

More information: "DNA Binding Alters Coactivator Interaction Surfaces of the Intact VDR/RXR Complex," by Jun Zhang et al., Nature Structural & Molecular Biology.

Related Stories

Study indicates vitamin A plays key role in the human body

Mar 17, 2011

In a recently-published study mapping the structure and function of the so-called "orphan" nuclear receptor TR4, Van Andel Research Institute (VARI) investigators suggest that Vitamin A may play a more direct role than ...

Gene-bender proteins may sway to DNA

Dec 04, 2006

Among the many genes packed into each cell of our body, those that get turned on, or expressed, are the ones that make us who we are. Certain proteins do the job of regulating gene expression by clasping onto key spots of ...

Common 'chaperone' protein found to work in surprising way

Apr 03, 2011

In the constantly morphing field of protein structure, scientists at The Scripps Research Institute offer yet another surprise: a common "chaperone" protein in cells thought to help other proteins fold has been shown instead ...

Recommended for you

Molecular gate that could keep cancer cells locked up

Jul 31, 2014

In a study published today in Genes & Development, Dr Christian Speck from the MRC Clinical Sciences Centre's DNA Replication group, in collaboration with Brookhaven National Laboratory (BNL), New York, ...

The 'memory' of starvation is in your genes

Jul 31, 2014

During the winter of 1944, the Nazis blocked food supplies to the western Netherlands, creating a period of widespread famine and devastation. The impact of starvation on expectant mothers produced one of the first known ...

Sugar mimics guide stem cells toward neural fate

Jul 30, 2014

Embryonic stem cells can develop into a multitude of cells types. Researchers would like to understand how to channel that development into the specific types of mature cells that make up the organs and other structures of ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Nairb
not rated yet Apr 11, 2011
Why develop new chemicals for these receptors before conducting tests in increased vitamin D and A levels. If these receptors already have a positive effect with these vitamins, this seems like a logical and cheap next step.

Am I missing something, or could it be that from a business model, an expencive and patentable drug is better than a cheap and readily available alternative.